Luis
Bujanda Fernández de Piérola
Tel Aviv University
Tel Aviv, IsraelPublications in collaboration with researchers from Tel Aviv University (12)
2024
-
Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance
American Journal of Gastroenterology, Vol. 119, Núm. 4, pp. 646-654
2023
-
Analysis of Clinical Phenotypes through Machine Learning of First-Line H. pylori Treatment in Europe during the Period 2013–2022: Data from the European Registry on H. pylori Management (Hp-EuReg)
Antibiotics, Vol. 12, Núm. 9
-
Author Correction: Comparison of the management of Helicobacter pylori infection between the older and younger European populations (Scientific Reports, (2023), 13, 1, (17235), 10.1038/s41598-023-43287-4)
Scientific Reports
-
Comparison of the management of Helicobacter pylori infection between the older and younger European populations
Scientific Reports, Vol. 13, Núm. 1
-
Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg)
Gut, Vol. 72, Núm. 6, pp. 1054-1072
-
Helicobacter pylori Diagnostic Tests Used in Europe: Results of over 34,000 Patients from the European Registry on Helicobacter pylori Management
Journal of Clinical Medicine, Vol. 12, Núm. 13
-
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease
Clinical Gastroenterology and Hepatology, Vol. 21, Núm. 3, pp. 771-788.e10
2022
-
Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)
Clinical Gastroenterology and Hepatology, Vol. 20, Núm. 10, pp. 2243-2257
-
Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)
Journal of Clinical Medicine, Vol. 11, Núm. 6
2021
-
European Registry on Helicobacter pylori management (Hp-EuReg): Patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients
Gut, Vol. 70, Núm. 1, pp. 40-54
-
Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders
Nature Genetics, Vol. 53, Núm. 11, pp. 1543-1552